Compass Therapeutics, Inc. (CMPX)
After hours:
| Previous Close | 1.6500 |
| Open | 1.7700 |
| Bid | 1.6900 x 500 |
| Ask | 1.7300 x 300 |
| Day's Range | 1.6800 - 1.7900 |
| 52 Week Range | 1.1500 - 3.6200 |
| Volume | |
| Avg. Volume | 371,174 |
| Market Cap | 233.901M |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study Top-line data readout for COMPANION-002, the Company’s randomized Phase 2/3 BTC U.S. study, is expected by the end of 2024 BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibo
- GlobeNewswire
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a checkpoint blocker. CTX-8371 is a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1.Compass advanced CTX-8371 to the clinic following pre-clinical observations of superior activity when compared with approved checkpoint blockers. BOSTON,
- GlobeNewswire
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference to be held at the Salt Palace Convention Center in Salt Lake City, Utah from April 17–19, 2024. Presentati
